SINCE 2005
jae hyung park
research group
We develop next-generation therapeutic and diagnostic platforms to modulate pathological microenvironments and biological responses. By integrating stimuli-responsive materials, immunotherapeutic biomaterials, engineered extracellular vesicles, and engineered microbial therapeutics, we aim to develop targeted therapeutic and diagnostic strategies for cancer, inflammatory diseases and degenerative diseases.
Research interests
Stimuli-responsive biomaterials
We develop biomaterials that respond selectively to pathological microenvironments or external stimuli. Our research focuses on functional materials such as stimuli-responsive organic and inorganic nanoparticles, self-immolative polymers, and hydrogels for targeted drug delivery, controlled drug release, and image-guided therapy.
Immunotherapeutic biomaterials
We develop therapeutic strategies to regulate immune responses and address therapeutic barriers in pathological microenvironments associated with cancer and inflammatory diseases. Our research focuses on engineering extracellular vesicles, developing activatable immunotherapeutics, and inducing immunogenic cell death to enhance therapeutic efficacy.
Engineered extracellular vesicles
We isolate and engineer extracellular vesicles (EVs) from various cell types, including stem cells, tumor cells, and immune cells. By preconditioning cells or engineering isolated EVs, we modulate their molecular cargo and surface properties. We also utilize peptides and polymers to modulate EV secretion in vivo. These strategies aim to promote tissue regeneration, suppress disease progression, and enhance the efficacy of immunotherapy.
Engineered microbial therapeutics
We engineer bacteria and yeast as living therapeutics by modifying their surfaces and programming them to express specific proteins. We also utilize extracellular vesicles derived from these microorganisms as cell-free therapeutic platforms. By harnessing their intrinsic functions and controlling their in vivo behavior, we aim to develop therapeutic strategies that deliver therapeutic agents, regulate immune responses, and modulate pathological microenvironments.
Recent publications
Kim CH, Ko H, Lee JA, Kim SH, Park MS, Lee CH, Shin S, Shin JM, Kang HG, Cho S, Chang J, Kim J, Jang WH, Kim M, Joshua A.J, Park JH*
Signal Transduction and Targeted Therapy 2026;11: 200 (IF: 81.2, JCR 0.3%)
Song M, Ha M, Shin S, Kim MJ, Son S, Lee JH, Hwang GW, Kim J, Duong VH, Park JH*, Pang CH*
Nano-Micro Letters 2026; 18:11 (IF: 38.5, JCR 1.0%)
Shin S, Ko H, Kim CH, Yoon BK, Son S, Lee JA, Shin JM, Lee J, Song SH, Joshua A.J*, Park JH*
Nature Materials 2023; 22:656-665 (IF: 41.2, JCR 0.3%)
Ghosh T, Jeon J, Duong VH, Ghahari F, Song SH, Kim J, Park M, Lee C, Kang H, Cho S, You DG, Lee J, Shin S, Choi HS, Chung CH, Park JH*
Advanced Materials 2026; 38:e10103 (IF: 29.1, JCR 2.0%)
Um W, Ko H, You DG, Lim S, Kwak G, Shim MK, Yang S, Lee J, Song Y, Kim K, Park JH*
Advanced Materials 2020; 32:1907953 (IF: 29.1, JCR 2.0%)